Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction

Exclusion Criteria

• •1. Myocardial infarction, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA (Transient Ischaemic Attack) in past 90 days prior to Visit 1
• •2. Contraindication to beta blocker
• •3. Heart transplant recipient or listed for heart transplant
• •4. Hospitalization plan for PCI, coronary artery bypass graft surgery, other cardiac invasive interventions (e.g. catheter ablation, pacemaker, CRT, ICD implantation)
• •5. Acute decompensated HF (Heart Failure)
• •6. Symptomatic hypotension or systolic blood pressure \< 100 mmHg)
• •7. Patients with CrCl \< 30 ml/min using creatinine-based CKD-EPI equations
• •8. Elevated liver enzymes (3 times over upper reference limit) or liver cirrhosis
• •9. Symptomatic bradycardia or heart rate \< 60/min
• •10. Allergy, adverse drug reaction, hypersensitivity to carvedilol
• •11. Life expectancy \< 6 months (e.g. metastatic malignancy)
• •12. Pregnancy, or women of childbearing age